What's in Instituto Mexicano del Seguro Social's pipeline?

Instituto Mexicano del Seguro Social has 11 drugs in our index: 7 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Instituto Mexicano del Seguro Social's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Merck Sharp & Dohme LLC, Assistance Publique Hopitaux De Marseille, AstraZeneca, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/instituto-mexicano-del-seguro-social.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Instituto Mexicano del Seguro Social — Portfolio Competitive Intelligence Brief

Instituto Mexicano del Seguro Social pipeline: 7 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Intravenous Lidocaine infusion + Standard Anesthesia	Intravenous Lidocaine infusion + Standard Anesthesia	marketed	Local anesthetic (sodium channel blocker)	Voltage-gated sodium channels	Anesthesia and Perioperative Pain Management
Doravirine + tenofovir DF + lamivudine	Doravirine + tenofovir DF + lamivudine	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase	Infectious Disease / Virology
collagen-povidone solution	collagen-povidone solution	marketed
Semaglutide (Rybelsus®)	Semaglutide (Rybelsus®)	marketed	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)	Diabetes
Saline Intraperitoneal Lavage	Saline Intraperitoneal Lavage	marketed			Surgery/Critical Care
Ondansetron Intraperitoneal Lavage	Ondansetron Intraperitoneal Lavage	marketed	5-HT3 receptor antagonist	5-HT3 receptor	Gastroenterology / Oncology
Perioperative magnesium sulfate	Perioperative magnesium sulfate	marketed	Electrolyte supplement / NMDA receptor antagonist	NMDA receptor, voltage-gated calcium channels	Perioperative medicine / Anesthesia
intravenous salin water	intravenous salin water	phase 3			Fluid and Electrolyte Management
Homologated placebo.	Homologated placebo.	phase 3

Therapeutic area mix

Anesthesia and Perioperative Pain Management · 1
Cardiovascular · 1
Diabetes · 1
Fluid and Electrolyte Management · 1
Gastroenterology / Oncology · 1
Infectious Disease / Virology · 1
Perioperative medicine / Anesthesia · 1
Surgery/Critical Care · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Assistance Publique Hopitaux De Marseille · 1 shared drug class
AstraZeneca · 1 shared drug class
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · 1 shared drug class
Beijing Chao Yang Hospital · 1 shared drug class
Beijing Dongfang Biotech Co., Ltd. · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Instituto Mexicano del Seguro Social:

Cite this brief

Drug Landscape (2026). Instituto Mexicano del Seguro Social — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-mexicano-del-seguro-social. Accessed 2026-05-16.